<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29852867</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5550</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Current protein &amp; peptide science</Title><ISOAbbreviation>Curr Protein Pept Sci</ISOAbbreviation></Journal><ArticleTitle>The Development of Peptide-based Antimicrobial Agents against Dengue Virus.</ArticleTitle><Pagination><StartPage>998</StartPage><EndPage>1010</EndPage><MedlinePgn>998-1010</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1389203719666180531122724</ELocationID><Abstract><AbstractText>Dengue fever has become an imminent threat to international public health because of global warming and climate change. The World Health Organization proclaimed that more than 50% of the world's population is at risk of dengue virus (DENV) infection. Therefore, developing a clinically approved vaccine and effective therapeutic remedy for treating dengue fever is imperative. Peptide drug development has become a novel pharmaceutical research field. This article reviews various peptidesbased antimicrobial agents targeting three pathways involved in the DENV lifecycle. Specifically, they are peptide vaccines from immunomodulation, peptide drugs that inhibit virus entry, and peptide drugs that interfere with viral replication. Many antiviral peptide studies against DENV have been conducted in animal model trials, and progression to clinical trials for these promising peptide drugs is anticipated.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yen-Wei</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chinese Medicine, E-DA Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chun-Ting</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ta-Chen</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chinese Medicine, E-DA Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Yun-Chung</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chinese Medicine, Kuanshan Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taitung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chih-Hui</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Mei</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Keng-Shiang</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>The School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Protein Pept Sci</MedlineTA><NlmUniqueID>100960529</NlmUniqueID><ISSNLinking>1389-2037</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023181">Antimicrobial Cationic Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023181" MajorTopicYN="N">Antimicrobial Cationic Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengue fever</Keyword><Keyword MajorTopicYN="N">antimicrobial agents</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">peptide drug</Keyword><Keyword MajorTopicYN="N">peptide vaccine.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29852867</ArticleId><ArticleId IdType="pmc">PMC6446661</ArticleId><ArticleId IdType="doi">10.2174/1389203719666180531122724</ArticleId><ArticleId IdType="pii">CPPS-EPUB-90827</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Messina J.P., Brady O.J., Scott T.W., Zou C., Pigott D.M., Duda K.A., Bhatt S., Katzelnick L., Howes R.E., Battle K.E., Simmons C.P., Hay S.I. Global spread of dengue virus types: Mapping the 70 year history. Trends Microbiol. 2014;22(3):138&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946041</ArticleId><ArticleId IdType="pubmed">24468533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., Sankoh O., Myers M.F., George D.B., Jaenisch T., Wint G.R., Simmons C.P., Scott T.W., Farrar J.J., Hay S.I. The global distribution and burden of dengue. Nature. 2013;496(7446):504&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Molyneux D.H., Savioli L., Engels D. Neglected tropical diseases: Progress towards addressing the chronic pandemic. Lancet. 2017;389(10066):312&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">27639954</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard D.S., Undurraga E.A., Halasa Y.A., Stanaway J.D. The global economic burden of dengue: A systematic analysis. Lancet Infect. Dis. 2016;16(8):935&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">27091092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales S., de Wet N., Maindonald J., Woodward A. Potential effect of population and climate changes on global distribution of dengue fever: An empirical model. Lancet. 2002;360(9336):830&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243917</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffner F., Mathis A. Dengue and dengue vectors in the WHO European region: Past, present, and scenarios for the future. Lancet Infect. Dis. 2014;14(12):1271&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pubmed">25172160</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina J.P., Brady O.J., Pigott D.M., Golding N., Kraemer M.U., Scott T.W., Wint G.R., Smith D.L., Hay S.I. The many projected futures of dengue. Nat. Rev. Microbiol. 2015;13(4):230&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">25730702</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M.G., Harris E. Dengue. Lancet. 2015;385(9966):453&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">25230594</ArticleId></ArticleIdList></Reference><Reference><Citation>Luz P.M., Vanni T., Medlock J., Paltiel A.D., Galvani A.P. Dengue vector control strategies in an urban setting: An economic modelling assessment. Lancet. 2011;377(9778):1673&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409589</ArticleId><ArticleId IdType="pubmed">21546076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa M.S., Rasotgi V., Jain S., Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control. Med. J. Armed Forces India. 2015;71(1):67&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297835</ArticleId><ArticleId IdType="pubmed">25609867</ArticleId></ArticleIdList></Reference><Reference><Citation>Normile D. Tropical medicine. Surprising new dengue virus throws a spanner in disease control efforts. Science. 2013;342(6157):415.</Citation><ArticleIdList><ArticleId IdType="pubmed">24159024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilakis N., Cardosa J., Hanley K.A., Holmes E.C., Weaver S.C. Fever from the forest: Prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat. Rev. Microbiol. 2011;9(7):532&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321645</ArticleId><ArticleId IdType="pubmed">21666708</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons C.P., Farrar J.J. Nguyen v, V.; Wills, B. Dengue. N. Engl. J. Med. 2012;366(15):1423&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">22494122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman A.L. Immunity to dengue virus: A tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 2011;11(8):532&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>St John A.L., Abraham S.N., Gubler D.J. Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis. Nat. Rev. Microbiol. 2013;11(6):420&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">23652323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B. Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology. Nat. Rev. Immunol. 2009;9(10):741&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">19763148</ArticleId></ArticleIdList></Reference><Reference><Citation>Screaton G., Mongkolsapaya J., Yacoub S., Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 2015;15(12):745&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">26603900</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu. Rev. Immunol. 2011;29:587&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">21219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Jumnainsong A., Onsirisakul N., Fitton P., Vasanawathana S., Limpitikul W., Puttikhunt C., Edwards C., Duangchinda T., Supasa S., Chawansuntati K., Malasit P., Mongkolsapaya J., Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328(5979):745&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Carod-Artal F.J., Wichmann O., Farrar J., Gascon J. Neurological complications of dengue virus infection. Lancet Neurol. 2013;12(9):906&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948177</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacoub S., Wertheim H., Simmons C.P., Screaton G., Wills B. Cardiovascular manifestations of the emerging dengue pandemic. Nat. Rev. Cardiol. 2014;11(6):335&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">24710495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bich T.D., Pham O.K., Hai D.H., Nguyen N.M., Van H.N., The T.D., Wills B., Yacoub S. A pregnant woman with acute cardiorespiratory failure: Dengue myocarditis. Lancet. 2015;385(9974):1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">25845796</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan M.N., Garcia-Blanco M.A. Targeting host factors to treat West Nile and dengue viral infections. Viruses. 2014;6(2):683&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939478</ArticleId><ArticleId IdType="pubmed">24517970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., Strauss J.H. Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell. 2002;108(5):717&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens A.J., Gahan M.E., Mahalingam S., Keller P.A. The medicinal chemistry of dengue fever. J. Med. Chem. 2009;52(24):7911&#x2013;7926.</Citation><ArticleIdList><ArticleId IdType="pubmed">19739651</ArticleId></ArticleIdList></Reference><Reference><Citation>Akey D.L., Brown W.C., Dutta S., Konwerski J., Jose J., Jurkiw T.J., DelProposto J., Ogata C.M., Skiniotis G., Kuhn R.J., Smith J.L. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science. 2014;343(6173):881&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263348</ArticleId><ArticleId IdType="pubmed">24505133</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit J.M., Moesker B., Rodenhuis-Zybert I., Wilschut J. Flavivirus cell entry and membrane fusion. Viruses. 2011;3(2):160&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206597</ArticleId><ArticleId IdType="pubmed">22049308</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H., Zhang B., Shi P.Y. Flavivirus methyltransferase: A novel antiviral target. Antiviral Res. 2008;80(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214650</ArticleId><ArticleId IdType="pubmed">18571739</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias N.G., Filomatori C.V., Gamarnik A.V. The F1 motif of dengue virus polymerase NS5 is involved in promoter-dependent RNA synthesis. J. Virol. 2011;85(12):5745&#x2013;5756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126321</ArticleId><ArticleId IdType="pubmed">21471248</ArticleId></ArticleIdList></Reference><Reference><Citation>Issur M., Geiss B.J., Bougie I., Picard-Jean F., Despins S., Mayette J., Hobdey S.E., Bisaillon M. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA. 2009;15(12):2340&#x2013;2350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779676</ArticleId><ArticleId IdType="pubmed">19850911</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche C., Holloway S., Schirmeister T., Klein C.D. Biochemistry and medicinal chemistry of the dengue virus protease. Chem. Rev. 2014;114(22):11348&#x2013;11381.</Citation><ArticleIdList><ArticleId IdType="pubmed">25268322</ArticleId></ArticleIdList></Reference><Reference><Citation>Schleich K., Nurnberger C., Sobanski A., Efferth T. Vaccination and antiviral treatment of neglected diseases caused by flaviviral infections. Curr. Med. Chem. 2011;18(4):604&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">21143108</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera R., Khaliq M., Kuhn R.J. Closing the door on flaviviruses: Entry as a target for antiviral drug design. Antiviral Res. 2008;80(1):11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646114</ArticleId><ArticleId IdType="pubmed">18585795</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlinson S.M., Pryor M.J., Wright P.J., Jans D.A. Dengue virus RNA polymerase NS5: A potential therapeutic target? Curr. Drug Targets. 2006;7(12):1623&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168837</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J. Developing a dengue vaccine: Progress and future challenges. Ann. N. Y. Acad. Sci. 2014;1323:140&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">24689974</ArticleId></ArticleIdList></Reference><Reference><Citation>Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">11807545</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliani A., Pirri G., Nicoletto S.F. Antimicrobial peptides: An overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2007;2(1):1&#x2013;33.</Citation></Reference><Reference><Citation>Sitaram N., Nagaraj R. The therapeutic potential of host-defense antimicrobial peptides. Curr. Drug Targets. 2002;3(3):259&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">12041739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz J., Ortiz C., Guzman F., Fernandez-Lafuente R., Torres R. Antimicrobial peptides: Promising compounds against pathogenic microorganisms. Curr. Med. Chem. 2014;21(20):2299&#x2013;2321.</Citation><ArticleIdList><ArticleId IdType="pubmed">24533812</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond G., Beckloff N., Weinberg A., Kisich K.O. The roles of antimicrobial peptides in innate host defense. Curr. Pharm. Des. 2009;15(21):2377&#x2013;2392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750833</ArticleId><ArticleId IdType="pubmed">19601838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mookherjee N., Hancock R.E. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 2007;64(7-8):922&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">17310278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollica A., Stefanucci A., Costante R. Strategies for developing tuberculosis vaccines: Emerging approaches. Curr. Drug Targets. 2013;14(9):938&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">23469877</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuerholz T., Domming S., Hornef M., Dupont A., Kowalski I., Kaconis Y., Heinbockel L., Andra J., Garidel P., Gutsmann T., David S., Sanchez-Gomez S., Martinez de Tejada G., Brandenburg K. Bacterial cell wall compounds as promising targets of antimicrobial agents II. Immunological and clinical aspects. Curr. Drug Targets. 2012;13(9):1131&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pubmed">22664073</ArticleId></ArticleIdList></Reference><Reference><Citation>Galdiero S., Falanga A., Berisio R., Grieco P., Morelli G., Galdiero M. Antimicrobial peptides as an opportunity against bacterial diseases. Curr. Med. Chem. 2015;22(14):1665&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pubmed">25760092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., Gallo R.L., Leung D.Y. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002;347(15):1151&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374875</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Biragyn A., Hoover D.M., Lubkowski J., Oppenheim J.J. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 2004;22:181&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15032578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock R.E., Lehrer R. Cationic peptides: A new source of antibiotics. Trends Biotechnol. 1998;16(2):82&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9487736</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters B.M., Shirtliff M.E., Jabra-Rizk M.A. Antimicrobial peptides: Primeval molecules or future drugs? PLoS Pathog. 2010;6(10):e1001067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965748</ArticleId><ArticleId IdType="pubmed">21060861</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyinloye B., Adenowo F., Gxaba N., Kappo A. The promise of antimicrobial peptides for treatment of human schistosomiasis. Curr. Drug Targets. 2014;15(9):852&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">25101908</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrent M., Pulido D., Rivas L., Andreu D. Antimicrobial peptide action on parasites. Curr. Drug Targets. 2012;13(9):1138&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">22664071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomara M.J., Haro I. Updating the use of synthetic peptides as inhibitors of HIV-1 entry. Curr. Med. Chem. 2014;21(10):1188&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">23931277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R.A., Pestonjamasp V., Piraino J., Huttner K., Gallo R.L. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414(6862):454&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719807</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur N., Qureshi A., Kumar M. AVPpred: Collection and prediction of highly effective antiviral peptides. Nucleic Acids Res., 2012, 40(Web Server issue), W199-W204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394244</ArticleId><ArticleId IdType="pubmed">22638580</ArticleId></ArticleIdList></Reference><Reference><Citation>Menard S., Forster V., Lotz M., Gutle D., Duerr C.U., Gallo R.L., Henriques-Normark B., Putsep K., Andersson M., Glocker E.O., Hornef M.W. Developmental switch of intestinal antimicrobial peptide expression. J. Exp. Med. 2008;205(1):183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234368</ArticleId><ArticleId IdType="pubmed">18180308</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschel A., Sahl H.G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 2006;4(7):529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">16778838</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez de Tejada G., Sanchez-Gomez S., Razquin-Olazaran I., Kowalski I., Kaconis Y., Heinbockel L., Andra J., Schurholz T., Hornef M., Dupont A., Garidel P., Lohner K., Gutsmann T., David S.A., Brandenburg K. Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines. Curr. Drug Targets. 2012;13(9):1121&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694180</ArticleId><ArticleId IdType="pubmed">22664072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudic M., Otvos L., Jr Intracellular targets of antibacterial peptides. Curr. Drug Targets. 2002;3(2):101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11958294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazrati E., Galen B., Lu W., Wang W., Ouyang Y., Keller M.J., Lehrer R.I., Herold B.C. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 2006;177(12):8658&#x2013;8666.</Citation><ArticleIdList><ArticleId IdType="pubmed">17142766</ArticleId></ArticleIdList></Reference><Reference><Citation>Doss M., White M.R., Tecle T., Gantz D., Crouch E.C., Jung G., Ruchala P., Waring A.J., Lehrer R.I., Hartshorn K.L. Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J. Immunol. 2009;182(12):7878&#x2013;7887.</Citation><ArticleIdList><ArticleId IdType="pubmed">19494312</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole A.M., Hong T., Boo L.M., Nguyen T., Zhao C., Bristol G., Zack J.A., Waring A.J., Yang O.O., Lehrer R.I. Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA. 2002;99(4):1813&#x2013;1818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122276</ArticleId><ArticleId IdType="pubmed">11854483</ArticleId></ArticleIdList></Reference><Reference><Citation>Furci L., Sironi F., Tolazzi M., Vassena L., Lusso P. Alpha-defensins block the early steps of HIV-1 infection: Interference with the binding of gp120 to CD4. Blood. 2007;109(7):2928&#x2013;2935.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132727</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshar M., Gallo R.L. Innate immune defense system of the skin. 2013.</Citation></Reference><Reference><Citation>Idrees S., Ashfaq U.A. Discovery and design of cyclic peptides as dengue virus inhibitors through structure-based molecular docking. Asian Pac. J. Trop. Med. 2014;7(7):513&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">25063278</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr K., Knox J.E., Phong W.Y., Ma N.L., Yin Z., Sampath A., Patel S.J., Wang W.L., Chan W.L., Rao K.R., Wang G., Vasudevan S.G., Keller T.H., Lim S.P. Yellow fever virus NS3 protease: Peptide-inhibition studies. J. Gen. Virol. 2007;88(Pt 8):2223&#x2013;2227.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622626</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusis P., Junaid M., Petrovska R., Yahorava S., Yahorau A., Katzenmeier G., Lapins M., Wikberg J.E. Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases. Biochem. Biophys. Res. Commun. 2013;434(4):767&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">23587903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Abdulrahman A.Y., Sasikumer P.G., Othman S., Rahman N.A., Yusof R. Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells. J. Biomed. Biotechnol. 2012;2012:251482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3470887</ArticleId><ArticleId IdType="pubmed">23093838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Bahrani H., Rahman N.A., Yusof R. Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus. BMC Microbiol. 2014;14:140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073510</ArticleId><ArticleId IdType="pubmed">24885331</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Han H.C., Ramasamy T.S., Othman S., Rahman N.A., Yusof R. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect. Dis. 2012;12:314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575220</ArticleId><ArticleId IdType="pubmed">23171075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan H.A., Mohamed Z., Suhaeb A.M., Rahman N.A., Yusof R. Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: High yield production of the biologically active recombinant plectasin peptide. OMICS. 2013;17(11):560&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814901</ArticleId><ArticleId IdType="pubmed">24044366</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuller A., Yin Z., Brian Chia C.S., Doan D.N., Kim H.K., Shang L., Loh T.P., Hill J., Vasudevan S.G. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Antiviral Res. 2011;92(1):96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambunan U.S., Alamudi S. Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. Bioinformation. 2010;5(6):250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055701</ArticleId><ArticleId IdType="pubmed">21364826</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Li H., Shao X., Fan C., Ericksen B., Liu J., Chi C., Wang C. Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease. J. Med. Chem. 2012;55(15):6881&#x2013;6887.</Citation><ArticleIdList><ArticleId IdType="pubmed">22780881</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Lim S.P., Beer D., Patel V., Wen D., Tumanut C., Tully D.C., Williams J.A., Jiricek J., Priestle J.P., Harris J.L., Vasudevan S.G. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem. 2005;280(31):28766&#x2013;28774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15932883</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrus S., Tambunan U.S., Zubaidi A.A. Designing cyclopentapeptide inhibitor as potential antiviral drug for dengue virus ns5 methyltransferase. Bioinformation. 2012;8(8):348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346019</ArticleId><ArticleId IdType="pubmed">22570514</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambunan U.S., Zahroh H., Utomo B.B., Parikesit A.A. Screening of commercial cyclic peptide as inhibitor NS5 methyltransferase of dengue virus through molecular docking and molecular dynamics simulation. Bioinformation. 2014;10(1):23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916815</ArticleId><ArticleId IdType="pubmed">24516322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazo L., Hermida L., Zulueta A., Sanchez J., Lopez C., Silva R., Guillen G., Guzman M.G. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine. 2007;25(6):1064&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097199</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin N., Aguilar A., Chamacho F., Vazquez Y., Pupo M., Ramirez J.C., Izquierdo L., Dafhnis F., Stott D.I., Perez E.M., Acosta A. Identification of Dengue-specific B-cell epitopes by phage-display random peptide library. Malays. J. Med. Sci. 2009;16(4):4&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216131</ArticleId><ArticleId IdType="pubmed">22135507</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez C., Gil L., Lazo L., Menendez I., Marcos E., Sanchez J., Valdes I., Falcon V., de la Rosa M.C., Marquez G., Guillen G., Hermida L. In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch. Virol. 2009;154(4):695&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">19305942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S., Chakravorty R., Ahmed M., Rahman A., Waise T.M., Hassan F., Rahman M., Shamsuzzaman S. A computational approach for identification of epitopes in dengue virus envelope protein: A step towards designing a universal dengue vaccine targeting endemic regions. In Silico Biol. 2010;10(5-6):235&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">22430357</ArticleId></ArticleIdList></Reference><Reference><Citation>Duangchinda T., Dejnirattisai W., Vasanawathana S., Limpitikul W., Tangthawornchaikul N., Malasit P., Mongkolsapaya J., Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. USA. 2010;107(39):16922&#x2013;16927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947904</ArticleId><ArticleId IdType="pubmed">20837518</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan K., Greenbaum J., Blythe M., Peters B., Sette A. Meta-analysis of all immune epitope data in the Flavivirus genus: Inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol. 2010;23(3):259&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942863</ArticleId><ArticleId IdType="pubmed">20565291</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Peng L., Zhao W., Zhong H., Zhang F., Yan Z., Cao H. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine. 2011;29(20):3695&#x2013;3702.</Citation><ArticleIdList><ArticleId IdType="pubmed">21419774</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil L., Bernardo L., Pavon A., Izquierdo A., Valdes I., Lazo L., Marcos E., Romero Y., Guzman M.G., Guillen G., Hermida L. Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J. Gen. Virol. 2012;93(Pt 6):1204&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">22398317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivino L., Kumaran E.A., Jovanovic V., Nadua K., Teo E.W., Pang S.W., Teo G.H., Gan V.C., Lye D.C., Leo Y.S., Hanson B.J., Smith K.G., Bertoletti A., Kemeny D.M., MacAry P.A. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J. Virol. 2013;87(5):2693&#x2013;2706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3571409</ArticleId><ArticleId IdType="pubmed">23255803</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., Broadwater A., Kolla R.V., De Silva A.D., de Silva A.M., Mattia K.A., Doranz B.J., Grey H.M., Shresta S., Peters B., Sette A. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. USA. 2013;110(22):E2046&#x2013;E2053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670335</ArticleId><ArticleId IdType="pubmed">23580623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil L., Izquierdo A., Lazo L., Valdes I., Ambala P., Ochola L., Marcos E., Suzarte E., Kariuki T., Guzman G., Guillen G., Hermida L. Capsid protein: Evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys. Virology. 2014;456-457:70&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">24889226</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza P., Campbell D., Marques E., Hildebrand W.H., Buchli R., Mailliard R., Rinaldo C.R. Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin. Exp. Immunol. 2014;177(3):696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137854</ArticleId><ArticleId IdType="pubmed">24816171</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha R.P., Livonesi M.C., Fumagalli M.J., Rodrigues N.F., da Costa L.C., Dos Santos M.C., de Oliveira Rocha E.S., Kroon E.G., Malaquias L.C., Coelho L.F. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II. Virus Res. 2014;188:122&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">24768848</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Guo X., Yan H., Fang D., Zeng G., Zhou J., Jiang L. Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM. Appl. Microbiol. Biotechnol. 2015;99(14):5917&#x2013;5927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4480844</ArticleId><ArticleId IdType="pubmed">25822571</ArticleId></ArticleIdList></Reference><Reference><Citation>Costin J.M., Jenwitheesuk E., Lok S.M., Hunsperger E., Conrads K.A., Fontaine K.A., Rees C.R., Rossmann M.G., Isern S., Samudrala R., Michael S.F. Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl. Trop. Dis. 2010;4(6):e721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889824</ArticleId><ArticleId IdType="pubmed">20582308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrobowski Y.M., Garry R.F., Michael S.F. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol. J. 2005;2:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177995</ArticleId><ArticleId IdType="pubmed">15927084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson C.O., Costin J.M., Rowe D.K., Lin L., Jenwitheesuk E., Samudrala R., Isern S., Michael S.F. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro. Antiviral Res. 2011;89(1):71&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">21093488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok S.M., Costin J.M., Hrobowski Y.M., Hoffmann A.R., Rowe D.K., Kukkaro P., Holdaway H., Chipman P., Fontaine K.A., Holbrook M.R., Garry R.F., Kostyuchenko V., Wimley W.C., Isern S., Rossmann M.G., Michael S.F. Release of dengue virus genome induced by a peptide inhibitor. PLoS One. 2012;7(11):e50995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511436</ArticleId><ArticleId IdType="pubmed">23226444</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A.G., Yang P.L., Harrison S.C. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog. 2010;6(4):e1000851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851732</ArticleId><ArticleId IdType="pubmed">20386713</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A.G., Yang P.L., Harrison S.C. Peptide inhibitors of flavivirus entry derived from the E protein stem. J. Virol. 2010;84(24):12549&#x2013;12554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004314</ArticleId><ArticleId IdType="pubmed">20881042</ArticleId></ArticleIdList></Reference><Reference><Citation>Laosutthipong C., Kanthong N., Flegel T.W. Novel, anionic, antiviral septapeptides from mosquito cells also protect monkey cells against dengue virus. Antiviral Res. 2013;98(3):449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">23603496</ArticleId></ArticleIdList></Reference><Reference><Citation>Panya A., Bangphoomi K., Choowongkomon K., Yenchitsomanus P.T. Peptide inhibitors against dengue virus infection. Chem. Biol. Drug Des. 2014;84(2):148&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">24612829</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikesit A.A. Kinanty; Tambunan, U.S. Screening of commercial cyclic peptides as inhibitor envelope protein dengue virus (DENV) through molecular docking and molecular dynamics. Pak. J. Biol. Sci. 2013;16(24):1836&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">24516999</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhoot M.A., Rathinam A.K., Wang S.M., Manikam R., Sekaran S.D. Inhibition of dengue virus entry into target cells using synthetic antiviral peptides. Int. J. Med. Sci. 2013;10(6):719&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638295</ArticleId><ArticleId IdType="pubmed">23630436</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., Reynales H., Costa M.S., Morales-Ramirez J.O., Carrasquilla G., Rey L.C., Dietze R., Luz K., Rivas E., Miranda Montoya M.C., Cortes Supelano M., Zambrano B., Langevin E., Boaz M., Tornieporth N., Saville M., Noriega F. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 2015;372(2):113&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">25365753</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Wongwiwat W., Supasa S., Zhang X., Dai X., Rouvinsky A., Jumnainsong A., Edwards C., Quyen N.T., Duangchinda T., Grimes J.M., Tsai W.Y., Lai C.Y., Wang W.K., Malasit P., Farrar J., Simmons C.P., Zhou Z.H., Rey F.A., Mongkolsapaya J., Screaton G.R. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 2015;16(2):170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G., Tan J.L., Smith S.A., de Alwis R., Ng T.S., Kostyuchenko V.A., Jadi R.S., Kukkaro P., de Silva A.M., Crowe J.E., Lok S.M. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat. Commun. 2015;6:6341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4346626</ArticleId><ArticleId IdType="pubmed">25698059</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., Luong C.Q., Rusmil K., Wirawan D.N., Nallusamy R., Pitisuttithum P., Thisyakorn U., Yoon I.K., van der Vliet D., Langevin E., Laot T., Hutagalung Y., Frago C., Boaz M., Wartel T.A., Tornieporth N.G., Saville M., Bouckenooghe A. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., Jiwariyavej V., Dulyachai W., Pengsaa K., Wartel T.A., Moureau A., Saville M., Bouckenooghe A., Viviani S., Tornieporth N.G., Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22975340</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M.G., Mune M., Kouri G. Dengue vaccine: Priorities and progress. Expert Rev. Anti Infect. Ther. 2004;2(6):895&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">15566333</ArticleId></ArticleIdList></Reference><Reference><Citation>Espada-Murao L.A., Morita K. Dengue and soluble mediators of the innate immune system. Trop. Med. Health. 2011;39(4) Suppl.:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317598</ArticleId><ArticleId IdType="pubmed">22500137</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: A review of candidates in preclinical development. Vaccine. 2011;29(42):7276&#x2013;7284.</Citation><ArticleIdList><ArticleId IdType="pubmed">21781998</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd Kadir S.L., Yaakob H., Mohamed Zulkifli R. Potential anti-dengue medicinal plants: A review. J. Nat. Med. 2013;67(4):677&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3765846</ArticleId><ArticleId IdType="pubmed">23591999</ArticleId></ArticleIdList></Reference><Reference><Citation>Abubakr M., Mandal S.C., Banerjee S. Natural compounds against flaviviral infections. Nat. Prod. Commun. 2013;8(10):1487&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">24354209</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.R., Ong E.Z., Ooi E.E. Therapeutic antibodies as a treatment option for dengue fever. Expert Rev. Anti Infect. Ther. 2013;11(11):1147&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">24093625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidari K.I., Abe T., Suzuki T. Carbohydrate-related inhibitors of dengue virus entry. Viruses. 2013;5(2):605&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640517</ArticleId><ArticleId IdType="pubmed">23389466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S.P., Wang Q.Y., Noble C.G., Chen Y.L., Dong H., Zou B., Yokokawa F., Nilar S., Smith P., Beer D., Lescar J., Shi P.Y. Ten years of dengue drug discovery: Progress and prospects. Antiviral Res. 2013;100(2):500&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">24076358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhakat S., Karubiu W., Jayaprakash V., Soliman M.E. A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. Eur. J. Med. Chem. 2014;87:677&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">25305334</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadir M.I., Abbas K., Tahir M., Irfan M., Raza Bukhari S.F., Ahmed B., Hanif M., Rasul A., Ali M. Dengue fever: Natural management. Pak. J. Pharm. Sci. 2015;28(2):647&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">25730815</ArticleId></ArticleIdList></Reference><Reference><Citation>Alen M.M., Schols D. Dengue virus entry as target for antiviral therapy. J. Trop. Med. 2012;2012:628475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317058</ArticleId><ArticleId IdType="pubmed">22529868</ArticleId></ArticleIdList></Reference><Reference><Citation>De La Guardia C., Lleonart R. Progress in the identification of dengue virus entry/fusion inhibitors. BioMed Res. Int. 2014;2014:825039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135166</ArticleId><ArticleId IdType="pubmed">25157370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew M.F., Poh K.S., Poh C.L. Peptides as therapeutic agents for dengue virus. Int. J. Med. Sci. 2017;14(13):1342&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5707751</ArticleId><ArticleId IdType="pubmed">29200948</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera R., Kuhn R.J. Structural proteomics of dengue virus. Curr. Opin. Microbiol. 2008;11(4):369&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581888</ArticleId><ArticleId IdType="pubmed">18644250</ArticleId></ArticleIdList></Reference><Reference><Citation>Botting C., Kuhn R.J. Novel approaches to flavivirus drug discovery. Expert Opin. Drug Discov. 2012;7(5):417&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190671</ArticleId><ArticleId IdType="pubmed">22439769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.F., Wang S.H., Sun C.M., Hu S.T., Syu W.J. Activation of dengue protease autocleavage at the NS2B-NS3 junction by recombinant NS3 and GST-NS2B fusion proteins. J. Virol. Methods. 2003;114(1):45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">14599678</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Patel S.J., Wang W.L., Wang G., Chan W.L., Rao K.R., Alam J., Jeyaraj D.A., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead. Bioorg. Med. Chem. Lett. 2006;16(1):36&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246553</ArticleId></ArticleIdList></Reference><Reference><Citation>Munk C., Wei G., Yang O.O., Waring A.J., Wang W., Hong T., Lehrer R.I., Landau N.R., Cole A.M. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses. 2003;19(10):875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">14585219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpe I.A., Gehrmann J., Loughnan M.L., Thomas L., Adams D.A., Atkins A., Palant E., Craik D.J., Adams D.J., Alewood P.F., Lewis R.J. Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter. Nat. Neurosci. 2001;4(9):902&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">11528421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol C.A., White L.J. Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front. Immunol. 2014;5:452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4174039</ArticleId><ArticleId IdType="pubmed">25309540</ArticleId></ArticleIdList></Reference><Reference><Citation>Clyde K., Kyle J.L., Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J. Virol. 2006;80(23):11418&#x2013;11431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1642597</ArticleId><ArticleId IdType="pubmed">16928749</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh R.M., Fujinami R.S. Pathogenic epitopes, heterologous immunity and vaccine design. Nat. Rev. Microbiol. 2007;5(7):555&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097378</ArticleId><ArticleId IdType="pubmed">17558423</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B., Almond J.W. Towards a dengue vaccine: Progress to date and remaining challenges. Comp. Immunol. Microbiol. Infect. Dis. 2008;31(2-3):239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">17889365</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Hombach J., Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine. 2009;27(3):355&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">19022321</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster D.P., Farrar J., Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect. Dis. 2009;9(11):678&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">19850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen L.R., Zhang G.L., Keskin D.B., Reinherz E.L., Brusic V. Conservation analysis of dengue virus T-cell epitope-based vaccine candidates using Peptide block entropy. Front. Immunol. 2011;2:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341948</ArticleId><ArticleId IdType="pubmed">22566858</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007;6(5):404&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473845</ArticleId></ArticleIdList></Reference><Reference><Citation>Comber J.D., Karabudak A., Huang X., Piazza P.A., Marques E.T., Philip R. Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum. Vaccin. Immunother. 2014;10(12):3531&#x2013;3543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514071</ArticleId><ArticleId IdType="pubmed">25668665</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch J., Standker L., Forssmann W.G., Kirchhoff F. Discovery of modulators of HIV-1 infection from the human peptidome. Nat. Rev. Microbiol. 2014;12(10):715&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097597</ArticleId><ArticleId IdType="pubmed">25110191</ArticleId></ArticleIdList></Reference><Reference><Citation>Currie S.M., Gwyer Findlay E., McFarlane A.J., Fitch P.M., Bottcher B., Colegrave N., Paras A., Jozwik A., Chiu C., Schwarze J., Davidson D.J. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J. Immunol. 2016;196(6):2699&#x2013;2710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777919</ArticleId><ArticleId IdType="pubmed">26873992</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar H.M., Rust M.J., Waarts B.L., van der Ende-Metselaar H., Kuhn R.J., Wilschut J., Zhuang X., Smit J.M. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J. Virol. 2007;81(21):12019&#x2013;12028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2168764</ArticleId><ArticleId IdType="pubmed">17728239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressanelli S., Stiasny K., Allison S.L., Stura E.A., Duquerroy S., Lescar J., Heinz F.X., Rey F.A. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004;23(4):728&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC380989</ArticleId><ArticleId IdType="pubmed">14963486</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y., Ogata S., Clements D., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA. 2003;100(12):6986&#x2013;6991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemesio H., Palomares-Jerez F., Villalain J. The membrane-active regions of the dengue virus proteins C and E. Biochim. Biophys. Acta. 2011;1808(10):2390&#x2013;2402.</Citation><ArticleIdList><ArticleId IdType="pubmed">21777566</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsch S., Miller S., Romero-Brey I., Merz A., Bleck C.K., Walther P., Fuller S.D., Antony C., Krijnse-Locker J., Bartenschlager R. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe. 2009;5(4):365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103389</ArticleId><ArticleId IdType="pubmed">19380115</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y., Ogata S., Clements D., Harrison S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427(6972):313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 2005;3(1):13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608696</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshuber S., Allison S.L., Heinz F.X., Mandl C.W. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 2003;84(Pt 1):183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">12533715</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller S., Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat. Rev. Microbiol. 2008;6(5):363&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096853</ArticleId><ArticleId IdType="pubmed">18414501</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu I.M., Zhang W., Holdaway H.A., Li L., Kostyuchenko V.A., Chipman P.R., Kuhn R.J., Rossmann M.G., Chen J. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008;319(5871):1834&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369148</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Lok S.M., Yu I.M., Zhang Y., Kuhn R.J., Chen J., Rossmann M.G. The flavivirus precursor membrane-envelope protein complex: Structure and maturation. Science. 2008;319(5871):1830&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369147</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera-Lecoin M., Meertens L., Carnec X., Amara A. Flavivirus entry receptors: An update. Viruses. 2014;6(1):69&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917432</ArticleId><ArticleId IdType="pubmed">24381034</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers T.J., Nestorowicz A., Amberg S.M., Rice C.M. Mutagenesis of the yellow fever virus NS2B protein: Effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J. Virol. 1993;67(11):6797&#x2013;6807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC238121</ArticleId><ArticleId IdType="pubmed">8411382</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B., Pethel M., Zhang Y.M., Lai C.J. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 1991;65(5):2467&#x2013;2475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240601</ArticleId><ArticleId IdType="pubmed">2016768</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Patel S.J., Wang W.L., Chan W.L., Rao R.K.R., Wang G., Ngew X., Patel V., Beer D., Knox J.E., Ma N.L., Ehrhardt C., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 2006;16(1):40&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer R.I. Primate defensins. Nat. Rev. Microbiol. 2004;2(9):727&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372083</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J., Holzgrabe U. Plectasin - a new peptide antibiotic with high therapeutic potential. Pharm. Unserer Zeit. 2010;39(5):336&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">20818681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mygind P.H., Fischer R.L., Schnorr K.M., Hansen M.T., Sonksen C.P., Ludvigsen S., Raventos D., Buskov S., Christensen B., De Maria L., Taboureau O., Yaver D., Elvig-Jorgensen S.G., Sorensen M.V., Christensen B.E., Kjaerulff S., Frimodt-Moller N., Lehrer R.I., Zasloff M., Kristensen H.H. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature. 2005;437(7061):975&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16222292</ArticleId></ArticleIdList></Reference><Reference><Citation>2014 https://chinapost.nownews.com/</Citation></Reference><Reference><Citation>BBC NEWS  2014 http://www.bbc.com/news/blogs-news-from-elsewhere-29850539</Citation></Reference><Reference><Citation>Jenssen H., Hamill P., Hancock R.E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006;19(3):491&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1539102</ArticleId><ArticleId IdType="pubmed">16847082</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentilucci L., De Marco R., Cerisoli L. Chemical modifications designed to improve peptide stability: Incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 2010;16(28):3185&#x2013;3203.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstrom R., Malmsten M. Delivery systems for antimicrobial peptides. Adv. Colloid Interface Sci. 2017;242:17&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">28159168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>